Professional Documents
Culture Documents
Med Info Response 2023-0071662-799194 PDF
Med Info Response 2023-0071662-799194 PDF
Rue Docteur-Yersin 12
1110 Morges
Switzerland
Tel +41 21 581 50 00
E-mail globalmedinfo@incyte.com
Web www.incyte.com
Lustinian Cretu
Romania
Ruxolitinib cream 1.5% for topical use is not approved by regulatory authorities for
marketed use in any country except the USA.
Under our industry’s code of practice, we are limited as to what information may be
provided to non-healthcare professionals.
We would like to recommend that you discuss your enquiry with your medical doctor. If
your medical doctor wants to receive additional information on the topic, he or she can
contact Incyte Medical Information as we can send him or her further information
directly.
If you have additional questions, or would like to report an adverse event or product
complaint, please contact us at globalmedinfo@incyte.com, eumedinfo@incyte.com or
the local number +443301003677.
I hope you find this information helpful. Please do not hesitate to contact me again if
you require anything further.
Yours sincerely,
Medical Information
2023-0071662
Page 2